Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...

1/7 Vertex Lane, Tonsley is a 1 bedroom apartment. What are the key property features of 1/7 Vertex Lane, Tonsley? To enquire about specific property features for 1/7 Vertex Lane, Tonsley, contact the ...

Situated in the coastal, marine resource-rich Qiucun Town, this project thus adopts an innovative fishery-PV model, with solar panels installed 2.5 meters above the fish ponds. This ensures continued ...

CEO David DeStefano stated, "Our third quarter performance demonstrated continued momentum in core strategic areas while managing specific market and customer headwinds." He highlighted strong cloud ...

$150 Million Class A Common Stock Repurchase Program On October 30, 2025, as part of the Company's capital allocation strategy to maximize long-term stockholder value, the Company’s Board of Directors ...

One challenge of using cell therapy to treat type 1 diabetes is that this approach requires chronic suppression of the immune system to prevent rejection of donor cells. A Vertex Pharmaceuticals ...

In contrast, Vertex’s other T1D therapy, zimislecel (formerly VX-880), is progressing positively. The Phase 3 portion of the Phase 1/2/3 study for zimislecel is on track to complete enrollment and ...

The addictive properties of opioids and the lives shattered by their misuse and overprescription are heavily chronicled chapters of the early 21st century. For over 2 decades, scientists in academia ...

Exclusively for WH+ members, The Women’s Health High Protein Meal Prep Manual is a nutritionist-designed guide that takes all the guesswork out of how much protein you need to feel your best every day ...